Journal
NEUROPHARMACOLOGY
Volume 149, Issue -, Pages 212-220Publisher
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.neuropharm.2019.02.026
Keywords
Acylethanolamides; Anandamide; Antidepressants; Depression; Endocannabinoids; Oleoylethanolamide; Primary care
Categories
Funding
- Ministerio de Economia y Competitividad, Instituto de Salud Carlos III (ISCIII)
- European Regional Development Funds-European Union (ERDF-EU) [RD12/0028/0001, RD16/0017/0001, PI16/01953, PI16/01689, PI17/02026]
- Ministerio de Sanidad, Asuntos Sociales e Igualdad and Plan Nacional sobre Drogas [PND2015/047, PND2017/043]
- Junta de Andalucia, Plan Andaluz de Investigacion, Desarrollo e Innovacion
- ERDF-EU [PAIDI CTS-433, CPII17/00024, CP14/00212, CP14/00173]
- DIUE de la Generalitat de Catalunya [2014SGR 680]
- University of Malaga
- Jose Castillejo Program the Spanish Ministry of Science, Innovation and Universities [CAS18/00263]
- Universidad de Malaga Incorporacion a Doctores, Plan Propio [CI-17-415]
- Consejeria de Salud y Bienestar Social, Junta de Andalucia [EF-2020-2017]
- ISCIII
- Consejeria de Salud, Junta de Andalucia
Ask authors/readers for more resources
Oleoylethanolamide (OEA) is a non-cannabinoid acylethanolamide with multiple physiological roles that has been proposed to have antidepressant-like activity in preclinical models. OEA shares biosynthetic pathways with anandamide (AEA) a transmitter involved in affective disorders and anxiety in humans. However, although the participation of OEA in depression has been proposed, both, the contribution of OEA to the depressive phenotype and the effect of antidepressant therapy on circulating levels of this and related non-cannabinoid acylethanolamides in humans are basically unknown. The main objective of this study is to compare the plasma concentrations of OEA and related acylethanolamides in a sample of primary care patients with depression (n = 69) with those of healthy non-depressed patients (n = 47). At the time of admission to the study, 22 patients were under selective serotonin reuptake inhibitor (SSRI) antidepressant treatment and 47 patients were not receiving any type of intervention. In addition, plasma concentrations of the endocannabinoid 2-AG and two related monoacylglycerols were monitored. Plasma OEA concentrations were found to be elevated in depressed patients and to correlate with somatic symptoms of depression. Plasma concentrations of both, AEA and 2-AG, were found to be elevated also in depressed patients. Further analysis demonstrated that the elevation observed in the plasma concentrations of both, OEA and 2-AG, was associated to SSRI antidepressant therapy at the time of recruitment. Further clinical research is needed to understand whether SSRI-induced elevations in OEA levels contribute to the response to SSRI in depressed patients as described in preclinical models.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available